Cargando…

Drug resistance in cancer

Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance. Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis evasion, cytochrome P450 and P-glycoprotein, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagüe, E, Raguz, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361669/
https://www.ncbi.nlm.nih.gov/pubmed/16234820
http://dx.doi.org/10.1038/sj.bjc.6602821
_version_ 1782153270244933632
author Yagüe, E
Raguz, S
author_facet Yagüe, E
Raguz, S
author_sort Yagüe, E
collection PubMed
description Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance. Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis evasion, cytochrome P450 and P-glycoprotein, were discussed. There was a special focus on leukaemia, breast and ovarian cancer, and the potential use of positron-emission tomography to study anticancer-drug resistance. The progress made in translating these findings to the clinic, like Gefitinib, P-glycoprotein phenotyping, or genome-wide analysis technology, was also discussed.
format Text
id pubmed-2361669
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23616692009-09-10 Drug resistance in cancer Yagüe, E Raguz, S Br J Cancer Meeting/Conference Report Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance. Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis evasion, cytochrome P450 and P-glycoprotein, were discussed. There was a special focus on leukaemia, breast and ovarian cancer, and the potential use of positron-emission tomography to study anticancer-drug resistance. The progress made in translating these findings to the clinic, like Gefitinib, P-glycoprotein phenotyping, or genome-wide analysis technology, was also discussed. Nature Publishing Group 2005-10-31 2005-10-18 /pmc/articles/PMC2361669/ /pubmed/16234820 http://dx.doi.org/10.1038/sj.bjc.6602821 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Meeting/Conference Report
Yagüe, E
Raguz, S
Drug resistance in cancer
title Drug resistance in cancer
title_full Drug resistance in cancer
title_fullStr Drug resistance in cancer
title_full_unstemmed Drug resistance in cancer
title_short Drug resistance in cancer
title_sort drug resistance in cancer
topic Meeting/Conference Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361669/
https://www.ncbi.nlm.nih.gov/pubmed/16234820
http://dx.doi.org/10.1038/sj.bjc.6602821
work_keys_str_mv AT yaguee drugresistanceincancer
AT raguzs drugresistanceincancer